ES3038026T3 - Altered virus - Google Patents

Altered virus

Info

Publication number
ES3038026T3
ES3038026T3 ES18701924T ES18701924T ES3038026T3 ES 3038026 T3 ES3038026 T3 ES 3038026T3 ES 18701924 T ES18701924 T ES 18701924T ES 18701924 T ES18701924 T ES 18701924T ES 3038026 T3 ES3038026 T3 ES 3038026T3
Authority
ES
Spain
Prior art keywords
virus
inhibitor
ctla
immune
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18701924T
Other languages
English (en)
Spanish (es)
Inventor
Robert Stuart Coffin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Replimune Ltd
Original Assignee
Replimune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replimune Ltd filed Critical Replimune Ltd
Application granted granted Critical
Publication of ES3038026T3 publication Critical patent/ES3038026T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES18701924T 2017-01-09 2018-01-09 Altered virus Active ES3038026T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1700350.0A GB201700350D0 (en) 2017-01-09 2017-01-09 Altered virus
PCT/GB2018/050048 WO2018127713A1 (en) 2017-01-09 2018-01-09 Altered virus

Publications (1)

Publication Number Publication Date
ES3038026T3 true ES3038026T3 (en) 2025-10-09

Family

ID=58463943

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18701924T Active ES3038026T3 (en) 2017-01-09 2018-01-09 Altered virus

Country Status (14)

Country Link
US (2) US12059444B2 (https=)
EP (2) EP3565568B1 (https=)
JP (2) JP7520511B2 (https=)
KR (2) KR20260047235A (https=)
CN (1) CN110198724B (https=)
AU (1) AU2018205763B2 (https=)
BR (1) BR112019013215A2 (https=)
CA (1) CA3049496A1 (https=)
DK (1) DK3565568T3 (https=)
ES (1) ES3038026T3 (https=)
GB (1) GB201700350D0 (https=)
IL (1) IL267949B2 (https=)
MX (2) MX2019008146A (https=)
WO (1) WO2018127713A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10612005B2 (en) 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
KR20180136435A (ko) 2016-01-27 2018-12-24 온코루스, 인크. 종양 살상형 바이러스 벡터 및 그의 용도
AU2017290828A1 (en) 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
AR111432A1 (es) 2017-04-28 2019-07-10 Merck Sharp & Dohme Biomarcadores para agentes terapéuticos contra el cáncer
US11612625B2 (en) 2017-07-26 2023-03-28 Oncorus, Inc. Oncolytic viral vectors and uses thereof
EP4029877B1 (en) 2017-08-03 2024-01-17 Amgen Inc. Interleukin-21 muteins and methods of treatment
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
TW201930344A (zh) 2018-01-12 2019-08-01 美商安進公司 抗ｐｄ-１抗體及治療方法
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
EA202192420A1 (ru) 2019-03-05 2021-12-13 Эмджен Инк. Применение онколитических вирусов для лечения рака
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
WO2020228828A1 (zh) * 2019-05-15 2020-11-19 郑州威瑞生物技术有限公司 诱导免疫细胞活性的组合物及使用该组合物治疗疾病的方法
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用
CN114555191A (zh) * 2019-05-29 2022-05-27 奥比思健康解决方案有限责任公司 用于表达嵌合受体的递送载体和颗粒及其使用方法
KR102834430B1 (ko) * 2019-08-16 2025-07-15 임비라 컴퍼니 리미티드 전신 투여용 종양용해성 단순 포진 바이러스를 포함하는 약학적 조성물
CN110982794B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种修饰的单纯疱疹病毒
CN110982795B (zh) * 2020-03-05 2020-06-16 北京唯源立康生物科技有限公司 一种单纯疱疹病毒及其用途
CN114075574A (zh) * 2020-08-19 2022-02-22 广东东阳光药业有限公司 构建体、溶瘤病毒及其应用
WO2024134495A1 (en) * 2022-12-20 2024-06-27 Janssen Biotech, Inc. Oncolytic virus and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5698531A (en) 1989-03-31 1997-12-16 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US6040169A (en) 1991-01-31 2000-03-21 Medical Research Council Herpes simplex virus-1 deletion variants and vaccines thereof
JP3974167B2 (ja) 1992-03-31 2007-09-12 アーチ デベロプメント コーポレイション 遺伝子，腫瘍及びウイルス感染の治療，並びにプログラムされた細胞死（アポプトーシス）を予防するための方法及び組成物
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
JPH11513390A (ja) 1995-10-06 1999-11-16 アーチ デベロップメント コーポレイション 細胞殺傷のウイルス増強のための方法および組成物
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
GB9700411D0 (en) * 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
US6428968B1 (en) 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
GB2375113B (en) 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
EP1381280B1 (en) 2001-03-27 2011-05-11 Catherex, Inc. Viral vectors and their use in therapeutic methods
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2006002394A2 (en) 2004-06-24 2006-01-05 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
WO2006048749A1 (en) 2004-11-04 2006-05-11 Pfizer Products Inc. Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer
ES2569409T3 (es) 2005-03-08 2016-05-10 Pfizer Products Inc. Composiciones de anticuerpo anti-CTLA-4
AU2006262021C1 (en) 2005-06-23 2012-05-10 The University Of Houston Use of mutant Herpes Simplex Virus-2 for cancer therapy
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
WO2009148488A2 (en) 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
RU2573912C2 (ru) 2008-10-08 2016-01-27 Интрексон Корпорейшн Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
EP2502078A1 (en) 2009-11-20 2012-09-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011119925A2 (en) 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2011118866A1 (ko) 2010-03-26 2011-09-29 연세대학교 산학협력단 네트워크를 통한 심사요청 방법
US20130243731A1 (en) 2010-09-24 2013-09-19 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2013112942A1 (en) 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
AU2013296919A1 (en) * 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
KR20210008155A (ko) 2012-08-30 2021-01-20 암젠 인크 단순 헤르페스 바이러스 및 면역 체크포인트 억제제를 사용한 흑색종의 치료방법
EP2912063A1 (en) 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
EP2968525A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
HUE042382T2 (hu) 2013-09-03 2019-06-28 Medimmune Ltd Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
HUE035875T2 (hu) * 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
BR112016009465A8 (pt) 2013-10-28 2018-01-30 Univ Pittsburgh Commonwealth Sys Higher Education vetor de hsv oncolítico.
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
WO2015128313A1 (en) * 2014-02-25 2015-09-03 Deutsches Krebsforschungszentrum Rna viruses for immunovirotherapy
MA39818A (fr) 2014-03-30 2017-02-08 Benevir Biopharm Inc Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
RU2696312C2 (ru) * 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
US20160040186A1 (en) * 2014-08-07 2016-02-11 Xiaoyun Liu Dna construct and method for transgene expression
GB201419579D0 (en) 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
WO2016118865A1 (en) 2015-01-23 2016-07-28 Dreamwell, Ltd. Automated mattress manufacturing process and apparatus
CN104987421A (zh) * 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
US10612005B2 (en) * 2016-01-08 2020-04-07 Replimune Limited Modified oncolytic virus
AU2016403583B2 (en) * 2016-04-22 2020-05-28 Immvira Co., Limited Construction of oncolytic herpes simplex viruses (oHSV) obligate vector and constructs for cancer therapy
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
JP2021527694A (ja) * 2018-06-21 2021-10-14 レプリミュン リミテッド 腫瘍溶解性ウイルスを用いた処置

Also Published As

Publication number Publication date
EP3565568B1 (en) 2025-08-06
MX2025002735A (es) 2025-04-02
EP4635984A2 (en) 2025-10-22
CN110198724A (zh) 2019-09-03
MX2019008146A (es) 2019-10-09
EP4635984A3 (en) 2025-12-24
GB201700350D0 (en) 2017-02-22
AU2018205763A1 (en) 2019-06-20
US20240358781A1 (en) 2024-10-31
CN110198724B (zh) 2025-03-18
DK3565568T3 (da) 2025-09-01
IL267949A (en) 2019-09-26
CA3049496A1 (en) 2018-07-12
US20190343903A1 (en) 2019-11-14
IL267949B1 (en) 2025-06-01
BR112019013215A2 (pt) 2019-12-10
EP3565568A1 (en) 2019-11-13
IL267949B2 (en) 2025-10-01
JP7813310B2 (ja) 2026-02-12
JP2020503871A (ja) 2020-02-06
JP7520511B2 (ja) 2024-07-23
US12059444B2 (en) 2024-08-13
KR20260047235A (ko) 2026-04-07
AU2018205763B2 (en) 2025-01-23
KR20190104055A (ko) 2019-09-05
WO2018127713A1 (en) 2018-07-12
JP2024095709A (ja) 2024-07-10

Similar Documents

Publication Publication Date Title
ES3038026T3 (en) Altered virus
US12397053B2 (en) Engineered virus
US20210252135A1 (en) Treatment using oncolytic virus
HK40008518B (en) Altered virus
HK40008518A (en) Altered virus
HK40049907A (en) Engineered virus
HK40049907B (en) Engineered virus